2026 Cholesterol Guideline May Shift Lipid-Lowering Therapy Toward Younger, Lower-Risk Adults: Study
USA: Three studies using nationally representative U.S. survey data projected the impact of the new dyslipidemia guideline. Although the guideline would not substantially increase the overall proportion of adults recommended for lipid-lowering therapy, it may shift treatment toward younger individuals and those at lower cardiovascular risk.
Among adults aged 40–79 years, the estimated proportion eligible for lipid-lowering therapy was nearly unchanged—49.6% under the 2026 guideline versus 49.4% previously—suggesting a change in the profile of treatment candidates rather than a major increase in the number of statin users.
A new study published in JAMA has found that the 2026 American Heart Association (AHA)/American College of Cardiology (ACC)/multisociety guideline on dyslipidemia substantially broadens eligibility for primary prevention statin therapy across the United States, with an estimated 21.5 million additional adults becoming eligible for treatment compared with previous recommendations.
The study was conducted by Timothy S. Anderson from the Division of General Internal Medicine, University of Pittsburgh, Pennsylvania, and colleagues. Researchers evaluated how the updated guideline would influence statin eligibility by analyzing data from the National Health and Nutrition Examination Survey (NHANES) collected between 2017 and 2023.
The cross-sectional analysis included 4,366 nonpregnant adults aged 30–79 years without known atherosclerotic cardiovascular disease (ASCVD), representing approximately 154.5 million U.S. adults. Participants had a weighted mean age of 51 years, and 52% were women.
The study led to the following findings:
- Under the 2026 dyslipidemia guideline, 56.6% of U.S. adults aged 30–79 years—an estimated 87.5 million people—would be eligible for primary prevention statin therapy, including 21.5 million adults who were not eligible under the 2018 guideline.
- 17.8% of participants were already receiving statins, while 8.6% qualified for statin therapy irrespective of ASCVD risk because of LDL cholesterol ≥190 mg/dL, diabetes, or chronic kidney disease. The remaining 68% required ASCVD risk assessment to guide treatment decisions.
- Statin eligibility increased substantially with age, reaching more than 93% among adults aged 70–79 years and 85% among those aged 60–69 years, compared with 11% among adults aged 30–39 years.
- Individuals newly eligible for statin therapy had a lower estimated 10-year ASCVD risk than those previously eligible (3.1% vs 6.1%), indicating that the updated guideline supports earlier preventive treatment in people at lower short-term cardiovascular risk.
The researchers concluded that the 2026 dyslipidemia guideline substantially expands the population recommended for primary prevention statin therapy, with much of the increase occurring among younger adults and individuals with relatively lower cardiovascular risk. They noted that the updated recommendations could lead to earlier cholesterol-lowering treatment in a broader segment of the population, potentially strengthening long-term cardiovascular disease prevention strategies.
Reference:
Anderson TS, Wilson LM, Sussman JB. Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy. JAMA. Published online July 20, 2026. doi:10.1001/jama.2026.11246
Next Story